DI BARTOLOMEO, MARIA CRISTINA
DI BARTOLOMEO, MARIA CRISTINA
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
2022 M. Ambrosini, M. Del Re, P. Manca, A. Hendifar, A. Drilon, G. Harada, A.H. Ree, S. Klempner, G.M. Mælandsmo, K. Flatmark, H.G. Russnes, J.M. Cleary, H. Singh, E. Sottotetti, A. Martinetti, G. Randon, A. Sartore-Bianchi, I. Capone, M. Milione, M. Di Bartolomeo, F. Pietrantonio
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
2022 G. Fucà, A. Raimondi, M. Prisciandaro, S. Lonardi, C. Cremolini, M. Ratti, M. Clavarezza, R. Murialdo, A. Sartore-Bianchi, V. Smiroldo, R. Berenato, P. Racca, F. Bergamo, S. Corallo, M. Di Bartolomeo, F. de Braud, F. Morano, F. Pietrantonio
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study
2021 A. Raimondi, S. Corallo, S. Lonardi, C. Antoniotti, L. Rimassa, A. Amatu, M. Tampellini, P. Racca, R. Murialdo, M. Clavarezza, A. Zaniboni, G. Toscano, G. Tomasello, F. Petrelli, L. Antonuzzo, M. Giordano, S. Cinieri, R. Longarini, M. Niger, M. Antista, M. Ambrosini, F. Pagani, M. Prisciandaro, G. Randon, F. de Braud, M. Di Bartolomeo, F. Pietrantonio, F. Morano
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer
2021 P. Manca, S. Corallo, G. Randon, S. Lonardi, C. Cremolini, L. Rimassa, F. Bergamo, C. Antoniotti, V. Smiroldo, A. Zaniboni, R. Murialdo, M. Tampellini, G. Tomasello, M. Clavarezza, P. Racca, M. Antista, A. Raimondi, M. Prisciandaro, F. Pagani, F. Palermo, F.G. Greco, M. Vaiani, M. Di Bartolomeo, F. de Braud, G. Calareso, F. Morano, F. Pietrantonio
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
2021 G. Fucà, F. Corti, M. Ambrosini, R. Intini, M. Salati, E. Fenocchio, P. Manca, C. Manai, F. Daniel, A. Raimondi, F. Morano, S. Corallo, M. Prisciandaro, A. Spallanzani, V. Quarà, C. Belli, M. Vaiani, G. Curigliano, C. Cremolini, F. De Braud, M. Di Bartolomeo, V. Zagonel, S. Lonardi, F. Pietrantonio
Perioperative Bevacizumab-based Triplet Chemotherapy in Patients with Potentially Resectable Colorectal Cancer Liver Metastases
2019 F. Pietrantonio, C. Cotsoglou, G. Fucà, S. Lo Vullo, F. Nichetti, M. Milione, J. Coppa, M. Vaiani, A. Alessi, M. Prisciandaro, M. Droz-Dit Busset, F. Morano, S. Corallo, S. Lazzat, M. Antista, A. Mennitto, G. Randon, A. Raimondi, A. Belfiore, B. Padovano, F. Perrone, L. Mariani, M. Di Bartolomeo, F. de Braud, V. Mazzaferro
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
2019 F. Pietrantonio, F. Morano, S. Corallo, R. Miceli, S. Lonardi, A. Raimondi, C. Cremolini, L. Rimassa, F. Bergamo, A. Sartore-Bianchi, M. Tampellini, P. Racca, M. Clavarezza, R. Berenato, M. Caporale, M. Antista, M. Niger, V. Smiroldo, R. Murialdo, A. Zaniboni, V. Adamo, G. Tomasello, M. Giordano, F. Petrelli, R. Longarini, S. Cinieri, A. Falcone, V. Zagonel, M. Di Bartolomeo, F. de Braud
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions
2017 R. Berenato, F. Morano, F. Pietrantonio, C. Cotsoglou, M. Caporale, G. Infante, A. Pellegrinelli, A. Alessi, C. Battiston, J. Coppa, B. Padovano, A. Mennitto, M. Niger, G. Fucà, S. Lazzati, G. Greco, G. Delconte, F. De Braud, V. Mazzaferro, M. Di Bartolomeo
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
2017 D. Oddo, G. Siravegna, A. Gloghini, C. Vernieri, B. Mussolin, F. Morano, G. Crisafulli, R. Berenato, G. Corti, C.C. Volpi, M. Buscarino, M. Niger, P.D. Dunne, G. Rospo, E. Valtorta, A. Bartolini, G. Fucà, S. Lamba, A. Martinetti, M. Di Bartolomeo, F. De Braud, A. Bardelli, F. Pietrantonio, F. Di Nicolantonio
Transcriptional and epigenetic phenomena in peripheral blood cells of monozygotic twins discordant for Alzheimer’s disease, a case report
2017 C. D'Addario, S.B. Candia, B. Arosio, M. Di Bartolomeo, C. Abbate, A. Casè, S. Candeletti, P. Romualdi, S. Damanti, M. Maccarrone, L..C. Bergamaschini, D. Mari
Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer : a systematic review and meta-analysis
2017 F. Petrelli, R. Berenato, L. Turati, A. Mennitto, F. Steccanella, M. Caporale, P. Dallera, F. de Braud, E. Pezzica, M. Di Bartolomeo, G. Sgroi, V. Mazzaferro, F. Pietrantonio, S. Barni
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan
2015 F.S. Falvella, S. Cheli, A. Martinetti, C. Mazzali, R. Iacovelli, C. Maggi, M. Gariboldi, M.A. Pierotti, M. Di Bartolomeo, E. Sottotetti, R. Mennitto, I. Bossi, F. de Braud, E. Clementi, F. Pietrantonio
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer : challenging drug label to light up new hope
2015 F. Pietrantonio, C. Cremolini, G. Aprile, S. Lonardi, A. Orlandi, A. Mennitto, R. Berenato, C. Antonio, M. Casagrande, V. Marsico, F. Marmorino, G.G. Cardellino, F. Bergamo, G. Tomasello, V. Formica, R. Longarini, E. Giommoni, M. Caporale, M. Di Bartolomeo, F. Loupakis, F. De Braud
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer : a systematic review and meta-analysis
2015 F. Pietrantonio, C. Cremolini, F. Petrelli, M. Di Bartolomeo, F. Loupakis, C. Maggi, C. Antoniotti, F. de Braud, A. Falcone, R. Iacovelli
A review on biomarkers for prediction of treatment outcome in gastric cancer
2013 F. Pietrantonio, F. De Braud, V. Da Prat, F. Perrone, M.A. Pierotti, M. Gariboldi, G. Fanetti, P. Biondani, A. Pellegrinelli, I. Bossi, M. Di Bartolomeo
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen
2012 F. Pietrantonio, P. Biondani, F. de Braud, A. Pellegrinelli, G. Bianchini, F. Perrone, B. Formisano, M. Di Bartolomeo